KDM1A and hepatocellular carcinoma: Of note, EZH2 (8.6 FC) and KDM1A (2 FC) are involved in tumor proliferation and metastasis and are recognized as prognostic/diagnostic biomarkers for HCC, implying that they are therapeutic targets for HCC treatments [10, 18].